Cover Image
市場調查報告書

非黑色素瘤性皮膚癌 : 開發平台分析

Nonmelanomatous Skin Cancer - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 213099
出版日期 內容資訊 英文 46 Pages
訂單完成後即時交付
價格
Back to Top
非黑色素瘤性皮膚癌 : 開發平台分析 Nonmelanomatous Skin Cancer - Pipeline Review, H2 2015
出版日期: 2015年11月30日 內容資訊: 英文 46 Pages
簡介

非黑色素瘤性皮膚癌,是指皮膚外層或上皮層的惡性增生。非黑色素瘤性皮膚癌通常從皮膚外層產生扁平表皮癌症或基底細胞癌症。據信太陽暴曬為非黑色素瘤性皮膚癌的重大風險要素。也存在暗示幼兒期承受大量的日光照射曬黑,是造成非黑色素瘤性皮膚癌發病的重大原因的證據。基底細胞癌症最大量發病的地方為臉部的皮膚,接著是耳朵、手背、肩膀、手臂。還有男性、女性發病率平均,40歲以上的人發病最多。

本報告提供全球各國的非黑色素瘤性皮膚癌治療用的開發中產品的開發情形相關分析、開發中產品的最新趨勢,及各臨床實驗階段的產品一覽、主要企業簡介、主要藥物概要(產品概要、功能機制、研究開發(R&D)的發展情形)、最新的產業趨勢等調查,並將其結果為您概述為以下內容。

簡介

  • 分析範圍

非黑色素瘤性皮膚癌概要

治療藥的開發

  • 非黑色素瘤性皮膚癌的開發中產品:概要
  • 非黑色素瘤性皮膚癌的開發中產品:比較分析

各企業開發中的非黑色素瘤性皮膚癌治療藥

大學/研究機關研究中的非黑色素瘤性皮膚癌治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

非黑色素瘤性皮膚癌治療藥:開發中的產品一覽(各企業)

非黑色素瘤性皮膚癌治療藥:研究中的產品一覽(各大學/研究機關)

非黑色素瘤性皮膚癌治療藥的開發企業

  • Advancell
  • EcoBiotics Limited
  • Hexima Limited
  • LEO Pharma A/S
  • Spherium Biomed S.L.

非黑色素瘤性皮膚癌:治療藥的評估

  • 單劑治療藥的情況
  • 各標靶
  • 各行動機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • ANS-401
  • ANS-403
  • EBC-46
  • OXT-328
  • 非黑色素瘤性皮膚癌用肽
  • 皮膚科學、免疫學、腫瘤學用基因重組肽
  • 皮膚科學、腫瘤用蛋白質激酶C 活躍小分子
  • 扁平表皮癌用PLK1 阻礙小分子
  • SP-12054
  • HPV相關的皮膚癌疫苗

非黑色素瘤性皮膚癌治療藥:最新的藥物簡介

非黑色素瘤性皮膚癌治療藥:開發暫停的產品

非黑色素瘤性皮膚癌治療藥:開發中止的產品

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7358IDB

Summary

Global Markets Direct's, 'Nonmelanomatous Skin Cancer - Pipeline Review, H2 2015', provides an overview of the Nonmelanomatous Skin Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Nonmelanomatous Skin Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nonmelanomatous Skin Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Nonmelanomatous Skin Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Nonmelanomatous Skin Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Nonmelanomatous Skin Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Nonmelanomatous Skin Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Nonmelanomatous Skin Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Nonmelanomatous Skin Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Nonmelanomatous Skin Cancer Overview
  • Therapeutics Development
    • Pipeline Products for Nonmelanomatous Skin Cancer - Overview
    • Pipeline Products for Nonmelanomatous Skin Cancer - Comparative Analysis
  • Nonmelanomatous Skin Cancer - Therapeutics under Development by Companies
  • Nonmelanomatous Skin Cancer - Therapeutics under Investigation by Universities/Institutes
  • Nonmelanomatous Skin Cancer - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Nonmelanomatous Skin Cancer - Products under Development by Companies
  • Nonmelanomatous Skin Cancer - Products under Investigation by Universities/Institutes
  • Nonmelanomatous Skin Cancer - Companies Involved in Therapeutics Development
    • Advancell
    • EcoBiotics Limited
    • Hexima Limited
    • LEO Pharma A/S
    • Spherium Biomed S.L.
  • Nonmelanomatous Skin Cancer - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ANS-40 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ANS-401 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ANS-403 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EBC-46 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OXT-328 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Peptide for Non-Melanoma Skin Cancer - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Peptide for Dermatology, Immunology and Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Activate Protein Kinase C for Dermatology and Cancer - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit PLK1 for Cutaneous Squamous Cell Carcinoma - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SP-12054 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for HPV Associated Skin Cancer - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Nonmelanomatous Skin Cancer - Recent Pipeline Updates
  • Nonmelanomatous Skin Cancer - Dormant Projects
  • Nonmelanomatous Skin Cancer - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Nonmelanomatous Skin Cancer, H2 2015
  • Number of Products under Development for Nonmelanomatous Skin Cancer - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Comparative Analysis by Unknown Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • Nonmelanomatous Skin Cancer - Pipeline by Advancell, H2 2015
  • Nonmelanomatous Skin Cancer - Pipeline by EcoBiotics Limited, H2 2015
  • Nonmelanomatous Skin Cancer - Pipeline by Hexima Limited, H2 2015
  • Nonmelanomatous Skin Cancer - Pipeline by LEO Pharma A/S, H2 2015
  • Nonmelanomatous Skin Cancer - Pipeline by Spherium Biomed S.L., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Nonmelanomatous Skin Cancer Therapeutics - Recent Pipeline Updates, H2 2015
  • Nonmelanomatous Skin Cancer - Dormant Projects, H2 2015
  • Nonmelanomatous Skin Cancer - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Nonmelanomatous Skin Cancer, H2 2015
  • Number of Products under Development for Nonmelanomatous Skin Cancer - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Targets, H2 2015
  • Number of Products by Stage and Targets, H2 2015
  • Number of Products by Mechanism of Actions, H2 2015
  • Number of Products by Stage and Mechanism of Actions, H2 2015
  • Number of Products by Routes of Administration, H2 2015
  • Number of Products by Stage and Routes of Administration, H2 2015
  • Number of Products by Molecule Types, H2 2015
  • Number of Products by Stage and Molecule Types, H2 2015
Back to Top